DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s000110050177, but it redirected us to https://link.springer.com/article/10.1007/s000110050177. The analysis below is for the second page.

Title[redir]:
The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis | Inflammation Research
Description:
Objective and Design: There is crucial evidence that leukotrienes are significant mediators of inflammation in inflammatory bowel diseases (IBD). Thus, selective inhibition of leukotriene synthesis is believed to provide a novel approach to therapy of IBD. The aim of the study is to study the efficacy of a potent 5-lipoxygenase activating protein inhibitor (FLAP), BAY y 1015 in a dextran sulfate model of mouse colitis.¶Material: Outbred female mice weighing approximately 25 grams were used to produce acute or chronic colitis by feeding 5% dextran sulfate in drinking water.¶Treatment: Colitic mice were treated with placebo (3% starch suspension, 0.1 ml. p.o., bid) or BAY y 1015 at 8 or 24 mg/kg, p.o., bid or olsalazine, 150 mg/kg/day, p.o.¶Methods: Efficacy was determined by measuring daily disease activity index (DAI), quantitative histological scores, qualitative histology and measurement of tissue myeloperoxidase (MPO) and leukotriene B4 (LTB4) levels.¶Results: BAY y 1015 was significantly more effective in improving the qualitative histology, inhibiting the DAI, inflammation scores (37–79%), crypt scores (28–71%), MPO (49–57%) and LTB4 levels (56–63%) compared to placebo treatment at all levels of colitis. The two doses of BAY y 1015 were equipotent in decreasing TLB4 levels. BAY y 1015 was significantly better than olsalazine in two of the three protocols used in this study. In the advanced disease level both doses of BAY y 1015 were equipotent in inhibiting crypt and (28–32%) inflammation scores (34–36%), LTB4 (34–56%) and MPO 41–49%) compared to olsalazine.¶Conclusion: This study suggests the possibility of investigating the use of this compound for the treatment of human inflammatory bowel diseases.

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, colitis, bay, dextran, sulfate, research, inflammation, murthy, access, privacy, cookies, content, information, publish, search, efficacy, model, mouse, inflammatory, bowel, study, mice, disease, scores, usa, data, log, journal, coppola, ibd, leukotriene, lipoxygenase, mpo, ltb, levels, open, discover, springer, function, optional, personal, parties, policy, find, track, published, february, cite, wood, explore,

Topics {✒️}

month download article/chapter dextran sulfate sodium dextran sulfate model inflammatory bowel diseases related subjects mouse colitis published advanced disease level lipoxygenase activating protein privacy choices/manage cookies full article pdf leukotriene b4 mouse colitis european economic area scope submit manuscript conditions privacy policy check access instant access quantitative histological scores accepting optional cookies 150 mg/kg/day decreasing tlb4 levels main content log chronic colitis journal finder publish article log leukotriene synthesis ibd research article cite article murthy colitic mice privacy policy personal data books a colitis 5-lipoxygenase inhibition optional cookies inflammation scores manage preferences 24 mg/kg data protection essential cookies cookies skip subscription content similar content institution subscribe journal publish crypt scores usage analysis social media varying standards

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis
         description: Objective and Design: There is crucial evidence that leukotrienes are significant mediators of inflammation in inflammatory bowel diseases (IBD). Thus, selective inhibition of leukotriene synthesis is believed to provide a novel approach to therapy of IBD. The aim of the study is to study the efficacy of a potent 5-lipoxygenase activating protein inhibitor (FLAP), BAY y 1015 in a dextran sulfate model of mouse colitis.¶Material: Outbred female mice weighing approximately 25 grams were used to produce acute or chronic colitis by feeding 5% dextran sulfate in drinking water.¶Treatment: Colitic mice were treated with placebo (3% starch suspension, 0.1 ml. p.o., bid) or BAY y 1015 at 8 or 24 mg/kg, p.o., bid or olsalazine, 150 mg/kg/day, p.o.¶Methods: Efficacy was determined by measuring daily disease activity index (DAI), quantitative histological scores, qualitative histology and measurement of tissue myeloperoxidase (MPO) and leukotriene B4 (LTB4) levels.¶Results: BAY y 1015 was significantly more effective in improving the qualitative histology, inhibiting the DAI, inflammation scores (37–79%), crypt scores (28–71%), MPO (49–57%) and LTB4 levels (56–63%) compared to placebo treatment at all levels of colitis. The two doses of BAY y 1015 were equipotent in decreasing TLB4 levels. BAY y 1015 was significantly better than olsalazine in two of the three protocols used in this study. In the advanced disease level both doses of BAY y 1015 were equipotent in inhibiting crypt and (28–32%) inflammation scores (34–36%), LTB4 (34–56%) and MPO 41–49%) compared to olsalazine.¶Conclusion: This study suggests the possibility of investigating the use of this compound for the treatment of human inflammatory bowel diseases.
         datePublished:2014-02-08T00:00:00Z
         dateModified:2014-02-08T00:00:00Z
         pageStart:224
         pageEnd:233
         sameAs:https://doi.org/10.1007/s000110050177
         keywords:
            Key words: 5-lipoxygenase inhibition — Five lipoxygenase activating protein (FLAP) — Dextran sulfate — Experimental colitis — Leukotriene B4— Inflammatory bowel disease
            Immunology
            Pharmacology/Toxicology
            Rheumatology
            Allergology
            Dermatology
            Neurology
         image:
         isPartOf:
            name:Inflammation Research
            issn:
               1420-908X
               1023-3830
            volumeNumber:46
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Birkhäuser-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:S. Murthy
               affiliation:
                     name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
                     address:
                        name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. S. Murthy
               affiliation:
                     name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
                     address:
                        name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. Coppola
               affiliation:
                     name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA
                     address:
                        name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA, US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. L. Wood
               affiliation:
                     name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA
                     address:
                        name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA, US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis
      description: Objective and Design: There is crucial evidence that leukotrienes are significant mediators of inflammation in inflammatory bowel diseases (IBD). Thus, selective inhibition of leukotriene synthesis is believed to provide a novel approach to therapy of IBD. The aim of the study is to study the efficacy of a potent 5-lipoxygenase activating protein inhibitor (FLAP), BAY y 1015 in a dextran sulfate model of mouse colitis.¶Material: Outbred female mice weighing approximately 25 grams were used to produce acute or chronic colitis by feeding 5% dextran sulfate in drinking water.¶Treatment: Colitic mice were treated with placebo (3% starch suspension, 0.1 ml. p.o., bid) or BAY y 1015 at 8 or 24 mg/kg, p.o., bid or olsalazine, 150 mg/kg/day, p.o.¶Methods: Efficacy was determined by measuring daily disease activity index (DAI), quantitative histological scores, qualitative histology and measurement of tissue myeloperoxidase (MPO) and leukotriene B4 (LTB4) levels.¶Results: BAY y 1015 was significantly more effective in improving the qualitative histology, inhibiting the DAI, inflammation scores (37–79%), crypt scores (28–71%), MPO (49–57%) and LTB4 levels (56–63%) compared to placebo treatment at all levels of colitis. The two doses of BAY y 1015 were equipotent in decreasing TLB4 levels. BAY y 1015 was significantly better than olsalazine in two of the three protocols used in this study. In the advanced disease level both doses of BAY y 1015 were equipotent in inhibiting crypt and (28–32%) inflammation scores (34–36%), LTB4 (34–56%) and MPO 41–49%) compared to olsalazine.¶Conclusion: This study suggests the possibility of investigating the use of this compound for the treatment of human inflammatory bowel diseases.
      datePublished:2014-02-08T00:00:00Z
      dateModified:2014-02-08T00:00:00Z
      pageStart:224
      pageEnd:233
      sameAs:https://doi.org/10.1007/s000110050177
      keywords:
         Key words: 5-lipoxygenase inhibition — Five lipoxygenase activating protein (FLAP) — Dextran sulfate — Experimental colitis — Leukotriene B4— Inflammatory bowel disease
         Immunology
         Pharmacology/Toxicology
         Rheumatology
         Allergology
         Dermatology
         Neurology
      image:
      isPartOf:
         name:Inflammation Research
         issn:
            1420-908X
            1023-3830
         volumeNumber:46
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Birkhäuser-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:S. Murthy
            affiliation:
                  name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
                  address:
                     name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. S. Murthy
            affiliation:
                  name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
                  address:
                     name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. Coppola
            affiliation:
                  name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA
                  address:
                     name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA, US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. L. Wood
            affiliation:
                  name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA
                  address:
                     name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA, US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Inflammation Research
      issn:
         1420-908X
         1023-3830
      volumeNumber:46
Organization:
      name:Birkhäuser-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
      address:
         name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
         type:PostalAddress
      name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
      address:
         name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
         type:PostalAddress
      name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA
      address:
         name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA, US
         type:PostalAddress
      name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA
      address:
         name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA, US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:S. Murthy
      affiliation:
            name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
            address:
               name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
               type:PostalAddress
            type:Organization
      name:N. S. Murthy
      affiliation:
            name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected]
            address:
               name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
               type:PostalAddress
            type:Organization
      name:D. Coppola
      affiliation:
            name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA
            address:
               name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA, US
               type:PostalAddress
            type:Organization
      name:D. L. Wood
      affiliation:
            name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA
            address:
               name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA, US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
      name:Krancer Center for IBD Research, Division of Gastroenterology and Hepatology, Hahnemann Division, Allegheny University of the Health Sciences, Mail Stop 131, Broad and Vine, Philadelphia, PA 19102-1192, USA, Fax +1 215 246 5432, e-mail: [email protected], US
      name:Department of Pathology, University of South Florida, College of Medicine, 12901 Bruce Down's Blvd., Tampa, FL 33612-4799, USA, US
      name:Bayer Research Corporation, 400 Morgan Lane, West Haven, CT 06516-4175, USA, US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(72)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.17s.